Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

Discover more about the study that analysed data from 1,757 urine samples collected as part of the Swiss Kidney Project on ...

Otsuka's experimental therapy for a potentially life-threatening kidney disease more than halved severe levels of protein in the urine of patients, intensifying the battle for an effective new ...

A subanalysis of the NeflgArd study shows benefits in eGFR and urine protein-creatinine ratio at baseline and across ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Otsuka's experimental drug for a type of kidney disease showed over 50% reduction in protein in patients' urine in a late-stage trial, the Japan-based company said on Friday. Patients treated with the ...

Otsuka's experimental drug reduced the levels of protein in urine by more than 50% in patients with a type of kidney disease, the Japan-based company said on Friday. The therapy, sibeprenlimab, ...